PMID- 8960447
OWN - NLM
STAT- MEDLINE
DCOM- 19970313
LR  - 20190512
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 17 Suppl F
DP  - 1996 Dec
TI  - The association between cardiac events and myocardial ischaemia following 
      thrombolysis in acute myocardial infarction and the impact of carvedilol.
PG  - 43-7
AB  - The majority of post-myocardial infarction studies with beta-blocking drugs 
      involved earlier generations. Newer drugs of this family with additional 
      vasodilating and free-radical suppression properties, such as carvediol, are now 
      available which may improve the prognosis still further. This double-blind, 
      randomized, placebo-controlled, parallel group study was designed to assess the 
      extent of myocardial ischaemia in clinically stable patients 6 weeks after acute 
      myocardial infarction and thrombolysis, and to determine the influence of 
      carvedilol on ischaemic events during the subsequent 6 months. One hundred and 
      one patients who remained event free at 6 weeks post myocardial infarction 
      underwent rest and exercise thallium-201 (TI-201) imaging. Reversible ischaemia 
      was detected in 70 of the patients and there were 13 events in this group 
      compared to one event in the 31 patients without ischaemia (P = 0.07). Four of 
      the 56 patients on carvedilol and 10 of the 45 on placebo had adverse cardiac 
      events (P = 0.04). In patients with reversible ischaemia carvedilol was more 
      effective in reducing these events than was placebo (P = 0.03). These studies 
      demonstrate that reversible myocardial ischaemia detected by TI-201 imaging is 
      present in a large proportion of clinically stable patients following 
      thrombolysis. In these patients, there is an increased cardiac event rate which 
      is significantly reduced by carvedilol.
FAU - Basu, S
AU  - Basu S
AD  - Department of Cardiology, Norwick Park Hospital, Harrow, Middlesex, UK.
FAU - Senior, R
AU  - Senior R
FAU - Raftery, E B
AU  - Raftery EB
FAU - Lahiri, A
AU  - Lahiri A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0 (Vasodilator Agents)
RN  - 0K47UL67F2 (Carvedilol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carbazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Carvedilol
MH  - Confidence Intervals
MH  - Coronary Angiography
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/diagnostic imaging/*drug therapy
MH  - Myocardial Ischemia/complications/diagnostic imaging/drug therapy
MH  - Pilot Projects
MH  - Prognosis
MH  - Propanolamines/administration & dosage/adverse effects/*therapeutic use
MH  - Survival Rate
MH  - Vasodilator Agents/administration & dosage/adverse effects/*therapeutic use
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1093/eurheartj/17.suppl_f.43 [doi]
PST - ppublish
SO  - Eur Heart J. 1996 Dec;17 Suppl F:43-7. doi: 10.1093/eurheartj/17.suppl_f.43.